EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Living drug carriers: Microbial and bioengineered platforms redefining precision therapeutic and immunomodulatory delivery

Lahanya Guha, Jonaid Ahmad Malik, Bipasha Bose

Journal of Controlled Release · 2026-11 · 399 · 115274

DOI: 10.1016/j.jconrel.2026.115274 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Lahanya Guha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka 575018, India. Hauptthemen laut MEDLINE: Drug Carriers, Drug Delivery Systems, Microorganisms, Genetically-Modified. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 383 Literaturangaben. Gefördert von: Indian Institute of Technology Ropar, Yenepoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microbial living therapeutics are a new class of drug-delivery materials that combine synthetic biology, immunomodulation, and advanced formulations to achieve controllable therapeutic effects in space and time. In the broad field of living drug-delivery systems, therapeutic platforms include engineered microorganisms, mammalian immune cells, stem cells, viral vectors, extracellular-vesicle-producing cells, and hybrid bioengineered living materials. This review focuses on engineered microbial living drug carriers, including genetically modified bacteria and probiotic platforms, because these systems uniquely integrate programmable biosensing, in situ therapeutic synthesis, adaptive immunomodulation, and controllable drug delivery within a single living chassis. Designed microbes and consortia possess other unique functions, such as microenvironment sensing, programmed control of gene expression, and long-lasting in situ manufacturing of therapeutic payloads not available with small-molecule or biologic drugs. Recent progress in microbial chassis engineering, genetic circuit design, and biocontainment has enabled fine-tuning of immune responses, metabolic pathways, and tissue-specific signaling in a wide range of diseases from cancer to autoimmune and inflammatory diseases, to metabolic and endocrine disorders, neuro-immunological conditions (e.g., amyotrophic lateral sclerosis), infectious diseases including infectious threats without existing approved vaccines (Zika virus) as well as rare genetic disorders. Advances in formulation science, including encapsulation technologies, biomaterial-microbe hybrids, and stimuli-responsive release platforms, have enabled overcoming key translation challenges concerning microbial viability, biodistribution, safety, and controlled activation in complex physiological milieus like the gut (for enteric pathogens), tumor microenvironment (for oncolytic organisms), or injured tissues (for tissue-targeting organisms). Increasing numbers of clinical-stage LBP studies are now conducted under good manufacturing practice, standardized QC, and clinical conditions, ranging from emerging PK, biodistribution, and biomarker-driven studies to those adapted to living entities. The addition of host microbiome profiling, multi-omics analysis, and computational modeling is anticipated to increase therapeutic predictability and patient stratification. Taken together, these advances position live microbial therapeutics as programmable biological medicines with the potential for adaptive, context-specific administration and warrant further clinical development and increased integration within precision medicine-informed therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CarriersDrug Delivery SystemsMicroorganisms, Genetically-ModifiedHumansAnimalsBioengineeringBacteriaProbiotics

Stichwörter der Autor:innen

Engineered probioticsImmunomodulatory drug deliveryLiving microbial therapeuticsProgrammable gene circuitsTargeted and controlled release systems

Substanzen

Drug Carriers

Autor:innen und Institutionen

  • Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka 575018, India.
  • Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, 140001, India. Electronic address: junaidpsst@gmail.com.
  • Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka 575018, India. Electronic address: bipasha.bose@yenepoya.edu.in.

Förderung

  • Indian Institute of Technology Ropar
  • Yenepoya University

Zitieren

APA

Guha, L., Malik, J. A., & Bose, B. (2026). Living drug carriers: Microbial and bioengineered platforms redefining precision therapeutic and immunomodulatory delivery. Journal of Controlled Release, 399, 115274. https://doi.org/10.1016/j.jconrel.2026.115274

Vancouver

Guha L, Malik JA, Bose B. Living drug carriers: Microbial and bioengineered platforms redefining precision therapeutic and immunomodulatory delivery. Journal of Controlled Release. 2026;399:115274. doi:10.1016/j.jconrel.2026.115274

BibTeX
@article{Guha2026,
  author = {Guha, Lahanya and Malik, Jonaid Ahmad and Bose, Bipasha},
  title = {Living drug carriers: Microbial and bioengineered platforms redefining precision therapeutic and immunomodulatory delivery},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {399},
  pages = {115274},
  doi = {10.1016/j.jconrel.2026.115274}
}
Kostenlos starten →